EUVIMEDEUVIMED entdecken
Crossref

Discovery, biological evaluation, and molecular modeling of novel alkylamine-based Cbl-b inhibitors

Jinyu Tu, Yi Guan, Xi Gu, Yan Wang, Haiwei Shen, Ruirui Yang, Li Zhang, Xingyong Liu, Jingyi Zhou, Zhili Zuo

Bioorganic Chemistry · 2026-08 · 177 · 109902

DOI: 10.1016/j.bioorg.2026.109902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-08. Verfasst von Jinyu Tu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong 643000, China; Zhejiang Key Laboratory of Intelligent Drug Discov…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-cbl, Drug Discovery, Adaptor Proteins, Signal Transducing, Amines. Die Arbeit nennt 18 Literaturangaben. Gefördert von: National Natural Science Foundation of China, University of the Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cbl-b, an E3 ubiquitin ligase, is a critical negative regulator of T-cell activation and an attractive target for cancer immunotherapy. Current small-molecule inhibitors largely rely on hydrophobic π-π stacking interactions with the gatekeeper residue Tyr363, which restricts the structural diversity of Cbl-b inhibitors and hinders the discovery of inhibitors with novel scaffolds. This study reports the stepwise optimization of the cyclic carbamate lead compound 5, eventually leading to the discovery of novel, representative alkylamine-based Cbl-b inhibitors. Our optimization process comprised three stages: (1) conformational restriction via lactamization, which yielded initial hit 12 (IC50 = 31.99 ± 3.88 μM); (2) hydrophobic cavity filling, which provided the improved analog 22 (IC50 = 8.58 ± 0.25 μM); and (3) SeeSAR-guided scaffold hopping, which ultimately identified the representative lead compound 27 (IC50 = 6.83 ± 0.51 μM). Molecular docking and molecular dynamics (MD) simulations confirmed that 27 binds to the TKB-LH interface and stabilizes the inactive conformation of Cbl-b. Notably, MD simulations revealed that 27 engages Tyr363 through a unique polar interaction mode dominated by hydrogen bonds and water bridges, a distinct departure from traditional hydrophobic stacking. This novel alkylamine scaffold provides a new approach for developing structurally diverse Cbl-b inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-cblDrug DiscoveryAdaptor Proteins, Signal TransducingAminesEnzyme InhibitorsHumansStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugMolecular Dynamics SimulationMolecular Docking SimulationModels, Molecular

Stichwörter der Autor:innen

Cbl-b inhibitorHydrogen bondsMolecular dynamicsWater bridges

Substanzen

Proto-Oncogene Proteins c-cblAdaptor Proteins, Signal TransducingAminesCBLB protein, humanEnzyme Inhibitors

Autor:innen und Institutionen

  • School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong 643000, China; Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, School of Pharmaceutical Science and Technology,…
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210046, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203,…
  • Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China; State Key Laboratory of Phytoc…
  • Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.
  • School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong 643000, China.
  • Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China; State Key Laboratory of Drug R…

Förderung

  • National Natural Science Foundation of China
  • University of the Chinese Academy of Sciences

Zitieren

APA

Tu, J., Guan, Y., Gu, X., Wang, Y., Shen, H., Yang, R., Zhang, L., Liu, X., Zhou, J., & Zuo, Z. (2026). Discovery, biological evaluation, and molecular modeling of novel alkylamine-based Cbl-b inhibitors. Bioorganic Chemistry, 177, 109902. https://doi.org/10.1016/j.bioorg.2026.109902

Vancouver

Tu J, Guan Y, Gu X, Wang Y, Shen H, Yang R, et al. Discovery, biological evaluation, and molecular modeling of novel alkylamine-based Cbl-b inhibitors. Bioorganic Chemistry. 2026;177:109902. doi:10.1016/j.bioorg.2026.109902

BibTeX
@article{Tu2026,
  author = {Tu, Jinyu and Guan, Yi and Gu, Xi and Wang, Yan and Shen, Haiwei and Yang, Ruirui and Zhang, Li and Liu, Xingyong and Zhou, Jingyi and Zuo, Zhili},
  title = {Discovery, biological evaluation, and molecular modeling of novel alkylamine-based Cbl-b inhibitors},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {177},
  pages = {109902},
  doi = {10.1016/j.bioorg.2026.109902}
}
Kostenlos starten →